Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/5521
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | de Wit, R. | - |
dc.contributor.author | Stoter, G. | - |
dc.contributor.author | Kaye, S.B. | - |
dc.contributor.author | Steijffer, D.Th. | - |
dc.contributor.author | Jones, W.G. | - |
dc.contributor.author | ten Bokkel Huinink, W.W. | - |
dc.contributor.author | Rea, L.A. | - |
dc.contributor.author | Collette, L. | - |
dc.contributor.author | SYLVESTER, Richard | - |
dc.date.accessioned | 2007-12-20T15:59:33Z | - |
dc.date.available | 2007-12-20T15:59:33Z | - |
dc.date.issued | 1997 | - |
dc.identifier.citation | Journal of clinical oncology, 15(5). p. 1837-1843 | - |
dc.identifier.uri | http://hdl.handle.net/1942/5521 | - |
dc.description.abstract | PURPOSE: This prospective randomized trial was designed to compare the efficacy of etoposide plus cisplatin (EP) versus bleomycin, etoposide, and cisplatin (BEP) chemotherapy in patients with good-prognosis metastatic nonseminomatous testicular cancer. PATIENTS AND METHODS: Four hundred nineteen patients with good-prognosis nonseminomatous testicular cancer were randomized to receive four cycles of cisplatin 20 mg/m2 on days 1 to 5 plus etoposide 120 mg/m2 on days 1, 3, and 5 with or without bleomycin 30 mg weekly. RESULTS: Of 395 eligible patients, 169 of 195 patients allocated to EP (87%) and 189 of 200 patients allocated to BEP (95%) achieved a complete response with chemotherapy alone or after postchemotherapy surgery. These results are significantly different (P = .0075). After a median follow-up duration of 7.3 years, eight patients (4%) on each treatment arm relapsed. In view of the low number of unfavorable treatment outcomes (11%), no significant differences were detected in time to progression (P = .136) and survival (P = .262). Both the acute and late pulmonary toxicity and neurotoxicity were significantly greater in patients who received BEP, whereas Raynaud's phenomenon occurred exclusively in patients who received BEP (P < .001). Two patients treated with BEP died of bleomycin pulmonary toxicity. CONCLUSION: BEP is the most effective combination regimen in the treatment of disseminated nonseminomatous germ cell cancer. In this particular BEP regimen with etoposide at a dose of 360 mg/m2 per cycle, even in good-prognosis patients, bleomycin cannot be deleted without compromising treatment efficacy, but its use is associated with more toxicity (particularly pulmonary) and efforts to reduce this merit further exploration. | - |
dc.language.iso | en | - |
dc.title | Importance of bleomycin in combination chemotherapy for good prognosis testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 1843 | - |
dc.identifier.issue | 5 | - |
dc.identifier.spage | 1837 | - |
dc.identifier.volume | 15 | - |
dc.bibliographicCitation.oldjcat | - | |
dc.identifier.url | http://jco.ascopubs.org/cgi/content/abstract/15/5/1837 | - |
item.fulltext | No Fulltext | - |
item.fullcitation | de Wit, R.; Stoter, G.; Kaye, S.B.; Steijffer, D.Th.; Jones, W.G.; ten Bokkel Huinink, W.W.; Rea, L.A.; Collette, L. & SYLVESTER, Richard (1997) Importance of bleomycin in combination chemotherapy for good prognosis testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. In: Journal of clinical oncology, 15(5). p. 1837-1843. | - |
item.accessRights | Closed Access | - |
item.contributor | de Wit, R. | - |
item.contributor | Stoter, G. | - |
item.contributor | Kaye, S.B. | - |
item.contributor | Steijffer, D.Th. | - |
item.contributor | Jones, W.G. | - |
item.contributor | ten Bokkel Huinink, W.W. | - |
item.contributor | Rea, L.A. | - |
item.contributor | Collette, L. | - |
item.contributor | SYLVESTER, Richard | - |
Appears in Collections: | Research publications |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.